drug
tocilizumab
Marketedupdated 5mo agoby Genentech Inc
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 8- tagApproval264 co-mentions · 72 sources
- drugACTEMRA253 co-mentions · 73 sources
- drugTYENNE16 co-mentions · 8 sources
- companyFresenius Kabi USA LLC8 co-mentions · 8 sources
- drugRNS-608 co-mentions · 8 sources
- drugAVTOZMA8 co-mentions · 4 sources
- companyCelltrion Inc4 co-mentions · 4 sources
- companyChugai Pharmaceutical Co Ltd1 co-mentions · 1 sources
indications
investigational
Rheumatoid Arthritis
all catalysts(61)
approval · 60
Jan 8, 2010
approval
ACTEMRA (TOCILIZUMAB) — FDA approval
tocilizumab
→
Jan 4, 2011
approval
ACTEMRA (TOCILIZUMAB) — FDA approval
tocilizumab
→
Jan 4, 2011
approval
ACTEMRA (TOCILIZUMAB) — FDA approval
tocilizumab
→
Jan 4, 2011
approval
ACTEMRA (TOCILIZUMAB) — FDA approval
tocilizumab
→
Apr 15, 2011
approval
ACTEMRA (TOCILIZUMAB) — FDA approval
tocilizumab
→
Apr 15, 2011
approval
ACTEMRA (TOCILIZUMAB) — FDA approval
tocilizumab
→
Jun 20, 2012
approval
ACTEMRA (TOCILIZUMAB) — FDA approval
tocilizumab
→
Aug 13, 2012
approval
ACTEMRA (TOCILIZUMAB) — FDA approval
tocilizumab
→
Oct 11, 2012
approval
ACTEMRA (TOCILIZUMAB) — FDA approval
tocilizumab
→
Apr 29, 2013
approval
ACTEMRA (TOCILIZUMAB) — FDA approval
tocilizumab
→
Jul 2, 2013
approval
ACTEMRA (TOCILIZUMAB) — FDA approval
tocilizumab
→
Oct 21, 2013
approval
ACTEMRA (TOCILIZUMAB) — FDA approval
tocilizumab
→
Oct 21, 2013
approval
ACTEMRA (TOCILIZUMAB) — FDA approval
tocilizumab
→
Nov 13, 2014
approval
ACTEMRA (TOCILIZUMAB) — FDA approval
tocilizumab
→
Aug 18, 2015
approval
ACTEMRA (TOCILIZUMAB) — FDA approval
tocilizumab
→
Aug 18, 2015
approval
ACTEMRA (TOCILIZUMAB) — FDA approval
tocilizumab
→
Sep 23, 2016
approval
ACTEMRA (TOCILIZUMAB) — FDA approval
tocilizumab
→
Sep 23, 2016
approval
ACTEMRA (TOCILIZUMAB) — FDA approval
tocilizumab
→
Mar 30, 2017
approval
ACTEMRA (TOCILIZUMAB) — FDA approval
tocilizumab
→
Mar 30, 2017
approval
ACTEMRA (TOCILIZUMAB) — FDA approval
tocilizumab
→
May 22, 2017
approval
ACTEMRA (TOCILIZUMAB) — FDA approval
tocilizumab
→
May 22, 2017
approval
ACTEMRA (TOCILIZUMAB) — FDA approval
tocilizumab
→
Aug 30, 2017
approval
ACTEMRA (TOCILIZUMAB) — FDA approval
tocilizumab
→
Mar 22, 2018
approval
ACTEMRA (TOCILIZUMAB) — FDA approval
tocilizumab
→
Mar 22, 2018
approval
ACTEMRA (TOCILIZUMAB) — FDA approval
tocilizumab
→
May 11, 2018
approval
ACTEMRA (TOCILIZUMAB) — FDA approval
tocilizumab
→
May 11, 2018
approval
ACTEMRA (TOCILIZUMAB) — FDA approval
tocilizumab
→
May 17, 2018
approval
ACTEMRA (TOCILIZUMAB) — FDA approval
tocilizumab
→
May 17, 2018
approval
ACTEMRA (TOCILIZUMAB) — FDA approval
tocilizumab
→
Sep 12, 2018
approval
ACTEMRA (TOCILIZUMAB) — FDA approval
tocilizumab
→
Sep 12, 2018
approval
ACTEMRA (TOCILIZUMAB) — FDA approval
tocilizumab
→
Nov 19, 2018
approval
ACTEMRA (TOCILIZUMAB) — FDA approval
tocilizumab
→
Nov 19, 2018
approval
ACTEMRA (TOCILIZUMAB) — FDA approval
tocilizumab
→
Dec 20, 2018
approval
ACTEMRA (TOCILIZUMAB) — FDA approval
tocilizumab
→
Dec 20, 2018
approval
ACTEMRA (TOCILIZUMAB) — FDA approval
tocilizumab
→
Apr 11, 2019
approval
ACTEMRA (TOCILIZUMAB) — FDA approval
tocilizumab
→
Apr 11, 2019
approval
ACTEMRA (TOCILIZUMAB) — FDA approval
tocilizumab
→
Apr 11, 2019
approval
ACTEMRA (TOCILIZUMAB) — FDA approval
tocilizumab
→
Jun 11, 2019
approval
ACTEMRA (TOCILIZUMAB) — FDA approval
tocilizumab
→
Jun 11, 2019
approval
ACTEMRA (TOCILIZUMAB) — FDA approval
tocilizumab
→
May 28, 2020
approval
ACTEMRA (TOCILIZUMAB) — FDA approval
tocilizumab
→
May 28, 2020
approval
ACTEMRA (TOCILIZUMAB) — FDA approval
tocilizumab
→
Mar 4, 2021
approval
ACTEMRA (TOCILIZUMAB) — FDA approval
tocilizumab
→
Mar 4, 2021
approval
ACTEMRA (TOCILIZUMAB) — FDA approval
tocilizumab
→
Oct 22, 2021
approval
ACTEMRA (TOCILIZUMAB) — FDA approval
tocilizumab
→
Oct 22, 2021
approval
ACTEMRA (TOCILIZUMAB) — FDA approval
tocilizumab
→
Feb 28, 2022
approval
ACTEMRA (TOCILIZUMAB) — FDA approval
tocilizumab
→
Feb 28, 2022
approval
ACTEMRA (TOCILIZUMAB) — FDA approval
tocilizumab
→
Dec 21, 2022
approval
ACTEMRA (TOCILIZUMAB) — FDA approval
tocilizumab
→
Dec 21, 2022
approval
ACTEMRA (TOCILIZUMAB) — FDA approval
tocilizumab
→
Sep 19, 2024
approval
ACTEMRA (TOCILIZUMAB) — FDA approval
tocilizumab
→
Sep 19, 2024
approval
ACTEMRA (TOCILIZUMAB) — FDA approval
tocilizumab
→
Sep 20, 2024
approval
ACTEMRA (TOCILIZUMAB) — FDA approval
tocilizumab
→
Sep 20, 2024
approval
ACTEMRA (TOCILIZUMAB) — FDA approval
tocilizumab
→
Dec 10, 2024
approval
ACTEMRA (TOCILIZUMAB) — FDA approval
tocilizumab
→
Dec 10, 2024
approval
ACTEMRA (TOCILIZUMAB) — FDA approval
tocilizumab
→
Aug 8, 2025
approval
ACTEMRA (TOCILIZUMAB) — FDA approval
tocilizumab
→
Aug 8, 2025
approval
ACTEMRA (TOCILIZUMAB) — FDA approval
tocilizumab
→
Dec 10, 2025
approval
ACTEMRA (TOCILIZUMAB) — FDA approval
tocilizumab
→
Dec 10, 2025
approval
ACTEMRA (TOCILIZUMAB) — FDA approval
tocilizumab
→
Trials studying tocilizumab
- phase1A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
- phase1A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
- phase2An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
- phase3A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- phase2A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma
- phase2Cevostamab in Combination With Pomalidomide and Dexamethasone After BCMA- Targeting CAR T-Cell Therapy in Participants With Previously Treated Multiple Myeloma
- phase3Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.
- phase3A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)
News(2)
- Fresenius Kabi Issues Nationwide Recall of Tyenne® (tocilizumab-aazg) Injection 400 mg/20 mL Vials Due to Presence of Glass ParticlesFOR IMMEDIATE RELEASE – August 10, 2026 – LAKE ZURICH, Ill.— Fresenius Kabi, an operating company of the Fresenius Group, is recalling one lot of Tyenne® (tocilizumab-aazg) Injection 400 mg/20 mL (…fda_medwatch · 2mo ago
- Dr Silbermann on Clinical Trial Design Considerations in Multiple MyelomaRebecca Silbermann, MD, MMS, outlines key trial design considerations in multiple myeloma, including supportive care measures and end point selection.onclive · 5mo ago
Data sources
last refreshed 49m ago
Found something off?
comments(0)
5-min edit window · permanent after that